This inventor holds 1 USPTO granted patent and 3 published patent applications and 1 EPO patent. Top assignee: Samsung Electronics Co., Ltd.. Active years: 2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2016
Title: Innovations of Sung Chun Cho in Muscle Wasting Treatment
Introduction
Sung Chun Cho is an accomplished inventor based in Incheon, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of muscle wasting-related diseases. His innovative work has the potential to improve the quality of life for many individuals suffering from muscle loss.
Latest Patents
Sung Chun Cho holds a patent for a pharmaceutical composition aimed at preventing or treating muscle wasting-related diseases. The patent, titled "Pharmaceutical composition for preventing or treating muscle wasting-related disease comprising diaminodiphenylsulfone or pharmaceutically acceptable salt thereof," describes a composition that includes diaminodiphenylsulfone (Dapsone; DDS) as an active ingredient. This composition is designed to effectively increase muscle mass, prevent muscle loss, and restore muscle function.
Career Highlights
Sung Chun Cho is currently associated with Samsung Electronics Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work is characterized by a commitment to developing effective treatments that address critical health issues.
Collaborations
He collaborates with notable colleagues, including Sang Chul Park and Young Hoon Son, who contribute to his research and development efforts. Their combined expertise enhances the potential impact of their innovations.
Conclusion
Sung Chun Cho's contributions to the field of pharmaceuticals, particularly in the treatment of muscle wasting-related diseases, highlight his role as a significant inventor. His innovative patent demonstrates a commitment to improving health outcomes for individuals affected by muscle loss.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
